These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25022707)

  • 1. Transarterial degradation of hyaluronic acid filler by hyaluronidase.
    DeLorenzi C
    Dermatol Surg; 2014 Aug; 40(8):832-41. PubMed ID: 25022707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transvascular Hydrolysis of Hyaluronic Acid Filler With Hyaluronidase: An Ex Vivo Study.
    Rauso R; Zerbinati N; Fragola R; Nicoletti GF; Tartaro G
    Dermatol Surg; 2021 Mar; 47(3):370-372. PubMed ID: 32932270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The duration of hyaluronidase and optimal timing of hyaluronic acid (HA) filler reinjection after hyaluronidase injection.
    Kim HJ; Kwon SB; Whang KU; Lee JS; Park YL; Lee SY
    J Cosmet Laser Ther; 2018 Feb; 20(1):52-57. PubMed ID: 29199877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid: in vitro and in vivo analysis, biochemical properties and histological and morphological evaluation of injected filler.
    Bertossi D; Sbarbati A; Cerini R; Barillari M; Favero V; Picozzi V; Ruzzenente O; Salvagno G; Guidi GC; Nocini P
    Eur J Dermatol; 2013; 23(4):449-55. PubMed ID: 24052368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Intra-arterial and Subcutaneous Testicular Hyaluronidase Injection Treatments and the Vascular Complications of Hyaluronic Acid Filler.
    Wang M; Li W; Zhang Y; Tian W; Wang H
    Dermatol Surg; 2017 Feb; 43(2):246-254. PubMed ID: 27930375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New High Dose Pulsed Hyaluronidase Protocol for Hyaluronic Acid Filler Vascular Adverse Events.
    DeLorenzi C
    Aesthet Surg J; 2017 Jul; 37(7):814-825. PubMed ID: 28333326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase.
    Buhren BA; Schrumpf H; Bölke E; Kammers K; Gerber PA
    Eur J Med Res; 2018 Aug; 23(1):37. PubMed ID: 30122153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Retrobulbar Hyaluronidase as a Treatment for Filler-Induced Blindness in a Cadaver Model.
    Paap MK; Milman T; Ugradar S; Silkiss RZ
    Plast Reconstr Surg; 2019 Aug; 144(2):315-320. PubMed ID: 31348334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time- and Dose-Dependent Effects of Hyaluronidase on the Degradation of Different Hyaluronan-Based Fillers In Vitro.
    Gerber PA; Buhren BA; Bölke E; Philipp-Dormston WG; Homey B; Schrumpf H
    Plast Reconstr Surg; 2023 Mar; 151(3):560-567. PubMed ID: 36730370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Kinetics of Reversible Hyaluronic Acid Filler Injection Treated With Hyaluronidase.
    Juhász MLW; Levin MK; Marmur ES
    Dermatol Surg; 2017 Jun; 43(6):841-847. PubMed ID: 28498207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous Intra-arterial Hyaluronidase Injection for Hyaluronic Acid Filler Embolism Threatening Skin Barrier Integrity: Implementation of a Stepwise Treatment Protocol.
    Fu Q; Zheng C; Zhou GW; Xu X; Lai LY; Sun XE; Zhang LX; Wu Q; Ding HF; Yang Y; Fu HJ; Chen ML
    Aesthetic Plast Surg; 2024 Feb; 48(4):747-751. PubMed ID: 37775575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The study of histological changes of the arterial vascular structure after hyaluronidase exposure.
    Wattanakrai P; Jurairattanaporn N; Rojhirunsakool S; Visessiri Y; Suwanchinda A; Thanasarnaksorn W
    J Cosmet Dermatol; 2018 Aug; 17(4):632-636. PubMed ID: 30091219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of Hylauronic Acid Fillers Using Hyaluronidase in an In Vivo Model.
    Ferraz RM; Sandkvist U; Lundgren B
    J Drugs Dermatol; 2018 May; 17(5):548-553. PubMed ID: 29742187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Percutaneous Intraarterial Facial/Supratrochlear Arterial Hyaluronidase Injection for Treatment of Vascular Embolism Resulting From Hyaluronic Acid Filler Cosmetic Injection.
    Zheng C; Fu Q; Zhou GW; Lai LY; Zhang LX; Zhang DQ; Chen GJ; Liang LM; Chen ML
    Aesthet Surg J; 2022 May; 42(6):649-655. PubMed ID: 34958671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Correlation Between Hyaluronic Acid Filler and Hyaluronidase.
    Hwang E; Song YS
    J Craniofac Surg; 2017 May; 28(3):838-841. PubMed ID: 28085765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An In Vitro Model Assessing the Penetration of Hyaluronidase through Optic Nerve Dura for Management of Hyaluronic Acid Facial Filler Embolism.
    Adulkar N; Cheng C; Lee L; Rasmussen S; Dolman PJ; Yin VT
    Plast Reconstr Surg; 2019 Jul; 144(1):43e-47e. PubMed ID: 31246809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications of injectable fillers, part 2: vascular complications.
    DeLorenzi C
    Aesthet Surg J; 2014 May; 34(4):584-600. PubMed ID: 24692598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-linked hyaluronic acid filler hydrolysis with hyaluronidase: Different settings to reproduce different clinical scenarios.
    Rauso R; Zerbinati N; Franco R; Chirico F; Ronchi A; Sesenna E; Colella G; Tartaro G
    Dermatol Ther; 2020 Mar; 33(2):e13269. PubMed ID: 32061001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular complications of hyaluronic acid fillers and the role of hyaluronidase in management.
    Kim DW; Yoon ES; Ji YH; Park SH; Lee BI; Dhong ES
    J Plast Reconstr Aesthet Surg; 2011 Dec; 64(12):1590-5. PubMed ID: 21807574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of hyaluronidase as an anticancer agent inhibiting CD44.
    Shakouri A; Parvan R; Adljouy N; Abdolalizadeh J
    Biomed Chromatogr; 2020 Jan; 34(1):e4709. PubMed ID: 31630417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.